Prolia - Home | Osteoporosis Treatment | Amgen

RELY ON PROLIA® AS PART OF A LONG-TERM TREATMENT STRATEGY TO HELP PROTECT PATIENTS FROM ONGOING RISK OF FRACTURES

References:
  1. Ström O, et al. Arch Osteoporos. 2011;6:59–155.
  2. Baron R, et al. Bone. 2011;48:677–92.
  3. Prolia® (denosumab) Summary of Product Characteristics. Amgen.
  4. Cummings SR, et al. N Engl J Med. 2009;361:756–65.
  5. Kendler DL, et al. J Bone Miner Res. 2010;25:72–81.
  6. Miller PD, et al. J Clin Endocrinol Metab. 2016;101:3163–70.
  7. Recknor C, et al. Obstet Gynecol. 2013;121:1291–9.
  8. Roux C, et al. Bone. 2014;58:48–54.
  9. Bolognese MA, et al. J Clinical Densitom. 2013;16:147–53.
  10. Khalid S, et al. Osteoporosis Int. 2017;28(Suppl 1):S64–5. Abstract presented at WCO-IOF-ESCEO 2017; OC21.
  11. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
  12. Freemantle N, et al. Osteoporos Int. 2012;23:317–26.
  13. Karlsson L, et al. Osteoporos Int. 2015;26:2401–11.
  14. Durden E, et al. Arch Osteoporos. 2017;12:22–30.
  15. Reyes C, et al. Osteoporos Int. 2017;28:2297–3004.
  16. Hadji P, et al. Osteoporos Int. 2016;26:2967–78.

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public